Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMI-137 fluorescence-guided surgery in penile and tongue cancer
NL-OMON48118Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of emi-137 in penile squamous cell carcinoma (PSCC) and squamous cell carcinoma of the tongue (TSCC) (2 cohorts), sponsored by Netherlands Cancer Institute. Started Dec 2019; status: recruiting.
02
Drugs
emi-137
03
Conditions
penile squamous cell carcinoma (PSCC)squamous cell carcinoma of the tongue (TSCC)
Beyond the preview
Go deeper on NL-OMON48118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48118.